Cervical cancer screening by Liquid-based cytology with human papillomavirus deoxyribonucleic acid testing in Maharat Nakhon Ratchasima Hospital
Article Sidebar
Main Article Content
Abstract
Cervical cancer is the second most common in woman worldwide, Screening with the Papanicolaou cytology was performed and false negative more than 50%. Liquid-based cytology, new method has been increase the chance of detecting abnormal cells and human papillomavirus can be detected in this specimen. Objectives: The incidence of cervical cancer screening with LBC, the percentage of detected high-risk human papillomavirus types, age interval was detected virus and the incidence of follow up case in abnormal cells or had detected virus. Methods: A descriptive retrospective study was performed in cervical cancer screening by liquid-based cytology with human papillomavirus testing in Maharat Nakhon Ratchasima Hospital during the period 2009-12. Results: Cervical cancer screening with LBC was performed in total of 74 women (0.26%), 4 cases were abnormal cytology. 15 cases (20.27%) were detected high-risk human papillomavirus types and age interval was 50-59 years. Further investigated were done in 8/15 cases (53.33%), results were low grade lesions (4 cases) and negative intraepithelial lesions or malignancy (4 cases). Conclusion: Repeat test by liquid-based cytology with human papillomavirus testing in abnormal conventional pap smear help improve the efficiency and accuracy. Abnormal cytology or detect high-risk human papillomavirus types in primary cervical cancer screening cases, which of patients will be investigated further to determine disorders and help diagnosed faster. The result is accurate.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Casamitjana M, Sala M, Ochoa, et al. Results of cervical cancer scrcening programme from an area of Barcelona (Spain) with a large immigrant population. Eur I Public Health 2009; 19(5):499-503.
Chen H, Shu HM, Chang ZL, et al. Efficacy ofpap test in combination with ThinPrep cytological test in screening for cervical cancer. Asian Pac J cancer Prev 2012; 13(4): 1651-5.
Dr. Amal Abd EI hafcz. Liquid basc cytology [homepage on the internet]. No date [cited 2012 Dec 20]. Available from: URL:http://www.medfac.mans.edu.eg/english/staff'amalabdelhafez/liquid%20based%20cytology.swf
Bosch FX, Lorincz A, Mu๑oz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J clin Pathol 2002 Apr; 55(4): 244-65.
Apgar BS, Brotzman G. HPV testing in the evaluation of the minimally abnormal papanicolaou smear. Am Fam Physician 1999 May; 59(10): 2794-800.
Morassc L, Davidov A, Castellanos MR. The role of human papillomavirus testing in cervical cancer screening. JAAPA 2009 Nov; 22(11): 20-3.
Bhatla N, Moda N. The clinical utity of HPV DNA testing in cervical cancer screening strategies. India J Med Res 2009 Sep; 130(3): 261-5.
Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000 Sep; 9(9): 945-51.
The ThinPrep difference [homepage on the internternet]. No date[cited 2012 Dec 20]. Available from: URL: http://www.thinprep.com/bcp/thinprep_difference/beyond_conventional_pap.html
Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. I Infect Dis 2005 Jun; 191(11): 1796-807.
รศ. พญ. สุรินทร์ทิพย์ เปี่ยมสมบูรณ์, Thi Prep pap test [homepage on the internet]. No date Icited 2012 Dec 20]. Available from: URL: http://www.bangkokhealth.nineweb.co.th/index.php/health/health-year/women/2222-ตินเพร็พ-thinprep-pap-test.html
Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytology abnormality. Cancer Res 2006 Oct, 66(20):10112-9.
Schiffman M, Wentzensen N. Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011 Mar; 103(5): 368-83.
Jin XW, Sikon A, Yen-Lieberman B. Cervical cancer screening: Less testing, smarter testing. Cleve Clin J Med 2011 Nov; 78(11): 737-47.
Negri G, Rigo B, Vitadello F, Mian C, Egarter-Vigl E. Abnormal cervicovaginal cytology with negative human papillomavirus testing. Cancer 2007 Oct; 111(5): 280-4.
Recio FO, Sahai Srivastava BI, Wong C, Hempling RE, Eltabbakh GH, Piver MS. The clinical valve of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears. Eur J Gynaccol Oncol 1998; 19(3): 203-8.